Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
暂无分享,去创建一个
Robert J Caiazzo | Brian C-S Liu | J. Richie | M. O'Leary | Robert J. Caiazzo | B. Liu | Michael P O'Leary | Jerome P Richie | Dennis J O'Rourke | Daniel A DiJohnson | James C Nelson | David Ure | J. Nelson | Dennis O'Rourke | Daniel A Dijohnson | David Ure
[1] Jian-ying Zhang. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. , 2004, Cancer detection and prevention.
[2] Joshua R. Ehrlich,et al. A native antigen “reverse capture” microarray platform for autoantibody profiling of prostate cancer sera , 2007, PROTEOMICS - Clinical Applications.
[3] T. Dörk,et al. Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping , 2001, The EMBO journal.
[4] Weiliang Qiu,et al. Development of a “reverse capture” autoantibody microarray for studies of antigen‐autoantibody profiling , 2006, Proteomics.
[5] Rajiv Dhir,et al. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. , 2010, Cancer research.
[6] J. Kros,et al. Differential expression of Hela‐type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells , 2005, The Journal of pathology.
[7] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[8] R. Nussenblatt,et al. Antinuclear autoantibodies in uveitis. , 1989, Clinical and experimental rheumatology.
[9] T. Niki,et al. DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. , 2003, Molecular cancer research : MCR.
[10] E. Tan,et al. Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer* , 2006, Molecular & Cellular Proteomics.
[11] T. Morita,et al. Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation , 2007 .
[12] Joshua LaBaer,et al. The sentinel within: exploiting the immune system for cancer biomarkers. , 2005, Journal of proteome research.
[13] Tom Misteli,et al. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression , 2008, Proceedings of the National Academy of Sciences.
[14] Alan W Partin,et al. PSA markers in prostate cancer detection. , 2003, The Urologic clinics of North America.
[15] M. Brawer,et al. Prostate‐specific antigen: Current status , 1999, CA: a cancer journal for clinicians.
[16] Jianjun Yu,et al. Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression*S , 2008, Molecular & Cellular Proteomics.
[17] T. Daniels,et al. Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis , 2005, The Prostate.
[18] Joshua R. Ehrlich,et al. The 'reverse capture' autoantibody microarray:a native antigen-based platform for autoantibody profiling , 2006, Nature Protocols.
[19] J. Koziol,et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] Jianjun Yu,et al. Autoantibody Signatures in Prostate Cancer , 2006 .
[21] O. Finn,et al. Immune response as a biomarker for cancer detection and a lot more. , 2005, The New England journal of medicine.
[22] S. Nilsson,et al. Prostasome‐derived proteins capable of eliciting an immune response in prostate cancer patients , 2006, International journal of cancer.